Furthermore, we analysed the diagnostic performance of cfDNA-based biomarkers combined with the PSA-based biomarker QfPSA and developed two additional PCa risk scores, which included assessments of QfPSA, cfDNA/mL, patient’s age, and methylated RASSF1A, MIR129-2, NRIP3, and SOX8 DNA sequences/mL. This evidence concerns the gene NRIP3 and posterior cortical atrophy.